Bronchiole

This is how tobacco damages our cells

Retrieved on: 
Friday, February 9, 2024

With the countless studies available today on the effects of tobacco use, we should have no trouble convincing ourselves and others of how harmful it is.

Key Points: 
  • With the countless studies available today on the effects of tobacco use, we should have no trouble convincing ourselves and others of how harmful it is.
  • The cells that make up our tissues, organs and body systems are sensitive to the effects of external toxic agents, many of which can be found in tobacco.
  • Many smokers not only accept this, but also ignore the serious danger it poses to the people around them.

Initial effects in the mouth and pharynx

  • When tobacco smoke enters our body, the first cells to receive it are in the mouth, nose and throat.
  • These effects on the immune system are also linked to a higher likelihood of developing cancer.
  • We also cannot forget that tobacco smoke robs us of our sense of taste and smell, leaving an almost continuous bitter taste in the mouth.

Lung damage

  • Furthermore, due to the direct damage caused by tobacco on the tissue that maintains the structure of the lungs, the bronchi and bronchioles become blocked, generating symptoms similar to suffocation.
  • As if that were not enough, people with COPD are also more likely to develop cardiovascular disease, and lung cancer.

Black tar and macrophages

  • We can cast our minds back to the previous image of my father’s pipe, black and sticky with tar.
  • It so happens that the lungs are rich in macrophages – special cells that play a key role in our immune systems by reacting to attacks, producing inflammatory responses.
  • These cells end up ingesting the tar from tobacco, and they eventually die loaded with this substance which builds up and gives a smoker’s lungs their characteristic blackened appearance.

Nicotine’s effects on neurons: dependence and addiction

  • As with any other compound that stimulates neurotransmitter receptors, permanent stimulation desensitises neurons.
  • This means that the neurons reduce the number of receptors, or change their sensitivity to the stimulant.
  • This desensitisation process can lead not only to nicotine dependence, but also to other diseases such as memory loss.


Guillermo López Lluch is a member of the Spanish Society of Cell Biology, the Spanish Society of Biochemistry and Molecular Biology, the Spanish Society of Geriatrics and Gerontology, the Society for Free Radical Research and the International Coenzyme Q10 Association. The research carried out by the author is financed by public funds from the Spanish Government or the Autonomous Government of Andalusia.

Prime Medicine Announces Recent Progress and Highlights 2023 Strategic Priorities

Retrieved on: 
Monday, January 9, 2023

CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today provided an update on recent advancements of its Prime Editing technology and progress across its initial pipeline of eighteen programs, and outlined its strategic priorities and expected milestones for 2023.

Key Points: 
  • Today, Prime Medicine announced new preclinical data demonstrating that Prime Editing-mediated removal of pathological repeats in vitro results in correction of hypermethylation at the FXN gene, restoring genetic function back to wild-type levels.
  • Off-target Safety Data: Prime Medicine is progressing a comprehensive suite of assays to evaluate the potential off-target activity of its Prime Editors.
  • Prime Medicine is using PCSK9 as a model system for developing its modular LNP delivery platform to the liver.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Nominate first development candidate for CGD in 1Q 2023.

Zambon to Attend the CHEST Annual Meeting 2022

Retrieved on: 
Friday, October 14, 2022

In addition, Zambon is sponsoring a learning theater focused on the current understanding of BOS, including its clinical features, diagnosis, progression and treatment options.

Key Points: 
  • In addition, Zambon is sponsoring a learning theater focused on the current understanding of BOS, including its clinical features, diagnosis, progression and treatment options.
  • This event is not part of the official CHEST Annual Meeting 2022 conference sessions.
  • This event is not endorsed by CHEST and does not reflect the views or opinions of CHEST.
  • In Europe, Zambon also plans to market and distribute, upon regulatory approval, an innovative oral formulation of riluzole for patients suffering with Amyotrophic Lateral Sclerosis (ALS).

ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530

Retrieved on: 
Monday, May 2, 2022

Results of in vivo studies presented at ISHLT demonstrate that once-daily administration of aerosolized ALTA-2530 achieved distribution to the distal regions of the lung.

Key Points: 
  • Results of in vivo studies presented at ISHLT demonstrate that once-daily administration of aerosolized ALTA-2530 achieved distribution to the distal regions of the lung.
  • , Altavant's Chief Medical Officer added, "Following lung transplant, inappropriate activation of the innate immune system has been shown to drive transplant rejection.
  • ALTA-2530 is currently in preclinical development at Altavant for the treatment of BOS and chemical lung injuries.
  • Altavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases.

Biomarker Data from Phase 1b/2 Investigator-sponsored Trial of Mereo’s Alvelestat in Bronchiolitis Obliterans Syndrome (BOS) at the ASH Annual Meeting

Retrieved on: 
Monday, December 13, 2021

These data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, GA by Annie Im, MD, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA.

Key Points: 
  • These data were presented at the 63rd American Society of Hematology (ASH) Annual Meeting in Atlanta, GA by Annie Im, MD, University of Pittsburgh, UPMC Hillman Cancer Center, Pittsburgh, PA.
  • Six patients had stable disease (2 with an improvement of 9% in FEV1), while 4 had improved symptoms at end of study.
  • The potential of alvelestat to impact the progression of lung fibrosis in this patient population is also exciting and warrants further evaluation.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date hereof.

WishGarden Herbs Expands Product Offering With Five New Expertly Crafted Herbal Liquid Extracts

Retrieved on: 
Tuesday, November 23, 2021

WishGarden possesses extensive scientific knowledge and a 40-plus year track record of herbal expertise.

Key Points: 
  • WishGarden possesses extensive scientific knowledge and a 40-plus year track record of herbal expertise.
  • WishGarden also expanded its portfolio of whole herbs with the introduction of Maca, Schisandra, and Yerba Mate.
  • These three herbs are featured in the new Rise & Shine herbal tincture.
  • WishGarden Herbs is a woman-owned, multi-generational company committed to providing artful whole herb liquid extracts that are fast-acting and gentle on the body.

Data from Investigator-sponsored Trial of Mereo BioPharma’s alvelestat in Bronchiolitis Obliterans Syndrome (BOS) Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 4, 2021

This was the first evidence of elevated elastase activity as detected by elastin breakdown in patients with BOS and chronic GVHD.

Key Points: 
  • This was the first evidence of elevated elastase activity as detected by elastin breakdown in patients with BOS and chronic GVHD.
  • Treatment with alvelestat was associated with progressive reduction of plasma desmosine levels over 8 weeks of within-subject dose escalation and reduction stimulated neutrophil elastase activity.
  • As the disease progresses, the bronchioles may become damaged and inflamed, leading to extensive scarring and blockage of the airways.
  • You should not place undue reliance on any forward-looking statements, which speak only as of the date hereof.

Global Respiratory Syncytial Virus Market Size and Epidemiology Report 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, August 30, 2021

The "Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Respiratory Syncytial Virus Market Size and Epidemiology (8MM), By Drug Type (Synagis, Other), By Dosage Form (Oral, Other), By Treatment Type (Immune prophylaxis, Other), By Distribution Channel (Clinics, Other) -Estimation & Forecast" report has been added to ResearchAndMarkets.com's offering.
  • The global respiratory syncytial virus market held a market size of USD 1,669.5 Million in 2020 and is expected to reach USD 4,202.6 Million by 2027.
  • Respiratory syncytial virus (RSV) is a respiratory virus which affects the lungs and its bronchioles.
  • Synagis is a drug to prevent severe respiratory syncytial virus in children and infants who are at high risk.

Cough and Cold Preparations Global Market Report 2021: COVID-19 Implications and Growth to 2030 - Antihistamines, Expectorants, Bronchodilators, Decongestants, Antibiotics - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 12, 2021

The "Cough and Cold Preparations Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cough and Cold Preparations Global Market Report 2021: COVID-19 Implications and Growth to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The cold and cough preparations market consists of sales of drugs for cold and cough.
  • Threat from substitute products such as generic and counterfeit drugs, is significantly restraining the global cold and cough preparations market.
  • Global Cough And Cold Preparations Market, Segmentation By Drug Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

Beyond Air to Present at the Oppenheimer & Co. Fall Healthcare Life Sciences and MedTech Summit

Retrieved on: 
Friday, September 11, 2020

Beyond Air is currently advancing its revolutionary LungFit in clinical trials for the treatment of severe lung infections such as SARS-CoV-2, bronchiolitis and nontuberculous mycobacteria (NTM).

Key Points: 
  • Beyond Air is currently advancing its revolutionary LungFit in clinical trials for the treatment of severe lung infections such as SARS-CoV-2, bronchiolitis and nontuberculous mycobacteria (NTM).
  • Additionally, Beyond Air is using ultra-high concentrations of NO with a proprietary delivery system, separate from the LungFit, to target certain solid tumors in the pre-clinical setting.
  • In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs.
  • Rather, forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made.